Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein yippee-like 3 (YPEL3)
- Target
- YPEL3
- Molecular classification
- Other (Yippee-like protein family, small zinc-finger-like protein)
01
Overview
Protein yippee-like 3 (YPEL3) is a small, evolutionarily conserved protein encoded by the YPEL3 gene, located on chromosome 16p11.2. It belongs to the yippee-like protein family and contains a zinc-finger-like motif. YPEL3 is transcriptionally regulated by p53 and is an important mediator of cellular senescence and apoptosis in both normal and tumor cells. It acts as a tumor suppressor, frequently downregulated in several cancers due to epigenetic silencing. Beyond its growth-inhibitory role, YPEL3 is fundamental for the development of myelinating glial cells—oligodendrocytes and Schwann cells—in the central and peripheral nervous system. Loss or mutation of YPEL3 can lead to defective myelination and peripheral neuropathies. Despite its biological significance, there are currently no approved drugs targeting YPEL3 directly, and its manipulation poses safety concerns due to its essential roles in cell viability and nervous system development[1][2][3][4][5].
- Other names
- YPEL3FKSG5MGC10500small unstable apoptotic protein (SUAP)protein yippee-like 3
02
Mechanism of action
No drugs known to target YPEL3 directly; function is intrinsic to cell signaling and senescence pathways
03
Biological functions
Cellular senescenceApoptosisCell growth inhibitionGlial cell (oligodendrocyte and Schwann cell) developmentMyelination of the nervous system
04
Disease associations
Cancer (tumor suppressor gene, especially in ovarian and other malignancies)Peripheral neuropathies (related to hypomyelination and glial defects)
05
Safety considerations
Loss-of-function or mutation can cause developmental neuropathies and hypomyelinationPotential broad impact on cell cycle and viability if targeted, given fundamental roles in senescence and glial development
06
Biomarkers
Downregulation in tumors (cancer diagnostic marker)Methylation status of YPEL3 promoter region (potential epigenetic tumor biomarker)
Beyond the preview
Go deeper on Protein yippee-like 3 (YPEL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein yippee-like 3 (YPEL3).